Regulators in Europe have granted the world's first approval of a vaccine against Ebola—and health officials are wasting no time in rolling it out.
The European Commission announced at the start of the week that it had granted a landmark marketing authorization of Merck's Ebola vaccine Ervebo. The vaccine has been in the works since the 2014 West African Ebola outbreak. It is now being used in the ongoing outbreak in the Democratic Republic of Congo based on a "compassionate use" protocol.
The current outbreak in the DRC has killed nearly 2,200 since August 2018, causing nearly 3,300 cases. The outbreak is the second-largest recorded, surpassed only by the 2014 West African outbreak that caused more than 11,000 deaths and 28,000 cases.